Medical Director, Providence Cancer Institute
Oncology
Dr. Michael Kraut, MD
|
|
Give Review
Michael Kraut practices Oncology. He attended Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. Michael Kraut is a published doctor and has 53 publications published. The lastest was: 'Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer.' Michael Kraut, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- The Effects of Amnestic Mild Cognitive Impairment on Go/NoGo Semantic Categorization Task Performance and Event-Related Potentials.
- Reproducibility of detecting silent cerebral infarcts in pediatric sickle cell anemia.
- Electrophysiological spatiotemporal dynamics during implicit visual threat processing.
- Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.
- Age-related changes in feature-based object memory retrieval as measured by event-related potentials.
- Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220.
- Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
- Depressive symptoms and brain volumes in older adults: a longitudinal magnetic resonance imaging study.
- Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
- Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
- The role of postoperative irradiation in the treatment of locally recurrent incompletely resected extra-abdominal desmoid tumors.
- The role of irradiation in the management of locally recurrent non-metastatic soft tissue sarcoma of extremity/trunkal locations.
- Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
- Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.
- Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
- Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergrou...
- Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemi...
- Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
- Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
- Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck.
- Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain.
- Long-term outcome of combined modality therapy in retroperitoneal and deep-trunk soft-tissue sarcoma: analysis of prognostic factors.
- Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
- Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Inte...
- A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer.
- Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
- One-year age changes in MRI brain volumes in older adults.
- Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
- A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
- 'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study.
- Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.
- Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical ...
- Antinuclear antibodies as potential markers of lung cancer.
- Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.
- Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer.
- Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer.
- Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line.
- Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
- Autoimmunity to collagen in human lung cancer.
- Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
- Effects of rhG-CSF, 5-fluorouracil and extramedullary irradiation on murine megakaryocytopoiesis in vivo.
- Chemoradiotherapy of esophageal carcinoma.
- A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
- Effect of calcium replacement on the hemodynamic changes associated with high dose interleukin-2 therapy.
- Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.
- Initial experience with a practical hyperfractionated accelerated radiotherapy regimen.
- 5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
- A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
- Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
- A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
- Preoperative combination chemotherapy for advanced stage head and neck cancer. Promising early results.
- West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes.
Schools
Albert Einstein College of Medicine of Yeshiva University
Boston University Hospital
Beth Israel HospHarvard Med School
Johns Hopkins University And Hospital
Doctors Specialties
- Neuroradiology
- Oncology
Accepted Insurances
Education
-
McGaw Medical Center of Northwestern University -
Wayne State University School of Medicine
Hospital
-
St. John Hospital and Medical Center -
University of Michigan Hospitals and Health Centers
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770524423 |
| Last Name Of The Provider | KRAUT |
| First Name Of The Provider | MICHAEL |
| View All |